(STRO) Sutro Biopharma - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 427m USD | Total Return: 220.3% in 12m
Avg Turnover: 7.92M
Qual. Beats: 0
Rev. Trend: 13.1%
Qual. Beats: 0
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio -2.8 is critical
Altman Z'' -12.56 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader
Sutro Biopharma (STRO) is a clinical-stage oncology company specialized in site-specific antibody-drug conjugates (ADCs) and protein synthesis. The firm utilizes its proprietary XpressCF and XpressCF+ platforms to develop targeted therapies for various solid tumors and hematological cancers. Its pipeline includes STRO-004, targeting tissue factor (TF), and STRO-003, targeting ROR1, alongside pneumococcal vaccine candidates VAX-24 and Vax-31 developed in partnership with Vaxcyte.
The company operates within the high-growth ADC sector, a field focused on improving the therapeutic index of chemotherapy by linking cytotoxic agents directly to antibodies. Sutro’s business model relies heavily on strategic collaborations and licensing agreements with established pharmaceutical entities like Astellas and Ipsen to fund development and expand commercial reach. Investors can further analyze these partnership structures and pipeline milestones on ValueRay.
- Clinical trial data for STRO-004 determines lead candidate commercial viability
- Milestone payments from Vaxcyte partnership provide critical non-dilutive capital funding
- Expansion of Ipsen and Astellas collaborations drives future revenue growth
- Regulatory approval progress for STRO-003 impacts long-term oncology market share
- High research and development expenses necessitate frequent capital market access
| Net Income: -153.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 10.90 > 1.0 |
| NWC/Revenue: 150.8% < 20% (prev 232.4%; Δ -81.60% < -1%) |
| CFO/TA -0.63 > 3% & CFO -151.6m > Net Income -153.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (131k) vs 12m ago -98.43% < -2% |
| Gross Margin: 93.27% > 18% (prev 89.14%; Δ 4.14% > 0.5%) |
| Asset Turnover: 35.36% > 50% (prev 20.67%; Δ 14.69% > 0%) |
| Interest Coverage Ratio: -2.85 > 6 (EBIT TTM -113.4m / Interest Expense TTM 39.9m) |
| A: 0.62 (Total Current Assets 221.0m - Total Current Liabilities 70.8m) / Total Assets 242.0m |
| B: -4.20 (Retained Earnings -1.02b / Total Assets 242.0m) |
| C: -0.40 (EBIT TTM -113.4m / Avg Total Assets 281.7m) |
| D: -0.22 (Book Value of Equity -66.9m / Total Liabilities 308.9m) |
| Altman-Z'' = -12.56 = D |
| DSRI: 0.61 (Receivables 12.5m/13.6m, Revenue 99.6m/66.4m) |
| GMI: 0.96 (GM 89.14% / 93.27%) |
| AQI: 2.74 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 1.50 (Revenue 99.6m / 66.4m) |
| TATA: -0.01 (NI -153.6m - CFO -151.6m) / TA 242.0m) |
| Beneish M = -1.99 (Cap -4..+1) = B |
As of June 12, 2026, the stock is trading at USD 26.48 with a total of 238,913 shares traded.
Over the past week, the price has changed by -7.67%,
over one month by -32.64%,
over three months by +7.91% and
over the past year by +220.27%.
Sutro Biopharma has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold STRO.
- StrongBuy: 4
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 48.2 | 81.9% |
P/E Forward = 10.0301
P/S = 4.2903
P/B = 2.1114
Revenue TTM = 99.6m USD
EBIT TTM = -113.4m USD
EBITDA TTM = -106.7m USD
Long Term Debt = 6.03m USD (estimated: total debt 13.6m - short term 7.60m)
Short Term Debt = 7.60m USD (from shortTermDebt, last quarter)
Debt = 13.6m USD (from shortLongTermDebtTotal, last quarter) (leases 13.6m already included)
Net Debt = -188.9m USD (calculated: Debt 13.6m - CCE 202.6m)
Enterprise Value = 238.4m USD (427.4m + Debt 13.6m - CCE 202.6m)
Interest Coverage Ratio = -2.85 (Ebit TTM -113.4m / Interest Expense TTM 39.9m)
EV/FCF = -1.74x (Enterprise Value 238.4m / FCF TTM -137.4m)
FCF Yield = -57.63% (FCF TTM -137.4m / Enterprise Value 238.4m)
FCF Margin = -137.9% (FCF TTM -137.4m / Revenue TTM 99.6m)
Net Margin = -154.2% (Net Income TTM -153.6m / Revenue TTM 99.6m)
Gross Margin = 93.27% ((Revenue TTM 99.6m - Cost of Revenue TTM 6.70m) / Revenue TTM)
Gross Margin QoQ = 91.20% (prev 86.06%)
Tobins Q-Ratio = 0.99 (Enterprise Value 238.4m / Total Assets 242.0m)
Interest Expense / Debt = 292.3% (Interest Expense 39.9m / Debt 13.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -89.6m (EBIT -113.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.90 (Total Current Assets 221.0m / Total Current Liabilities 76.3m)
Debt / Equity = -0.20 (negative equity) (Debt 13.6m / totalStockholderEquity, last quarter -66.9m)
Debt / EBITDA = 1.77 (negative EBITDA) (Net Debt -188.9m / EBITDA -106.7m)
Debt / FCF = 1.38 (negative FCF - burning cash) (Net Debt -188.9m / FCF TTM -137.4m)
Total Stockholder Equity = -79.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.53% (Net Income -153.6m / Total Assets 242.0m)
RoE = 192.8% (negative equity) (Net Income TTM -153.6m / Total Stockholder Equity -79.7m)
RoCE = 154.0% (negative capital employed) (EBIT -113.4m / Capital Employed (Equity -79.7m + L.T.Debt 6.03m))
RoIC = -51.55% (negative operating profit) (NOPAT -89.6m / Invested Capital 173.8m)
WACC = 12.48% (E(427.4m)/V(441.0m) * Re(12.88%) + (debt cost/tax rate unavailable))
Discount Rate = 12.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: -81.87%
[DCF] Fair Price = unknown (Cash Flow -137.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 13.08 | Revenue CAGR: 6.56% | SUE: 0.41 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.39 | Chg30d=N/A | Revisions=N/A | Analysts=3
EPS next Quarter (2026-09-30): EPS=-2.46 | Chg30d=N/A | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=-7.80 | Chg30d=-16.29% | Revisions=-20% | GrowthEPS=+51.8% | GrowthRev=-57.0%
EPS next Year (2027-12-31): EPS=-6.88 | Chg30d=-177.62% | Revisions=-20% | GrowthEPS=+11.8% | GrowthRev=-28.2%
[Analyst] Revisions Ratio: -20%